Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide
Economic impact of diagnostic testing
10 evidence topics · 12 sources
Genetic testing rates before PARP inhibitor approval: United States oncology records
“Of 5213 mCRPC patients, 674 (13%) had a documented genetic test. The number of tested patients increased from 1 in 2013 to 313 in 2018 (out of 3161 and 3010 clinically active patients, respectively). Receiving care in an academic oncology center (versus a community-based center) strongly predicted genetic testing (hazard ratio = 2.41).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Biomarker testing rates in metastatic prostate cancer: United States community oncology network
“For these metastatic subgroups, biomarker testing rates were 80% (NSCLC), 34% (prostate), and 42% (bladder). Median time from disease diagnosis to first test order was 10 days (NSCLC), 98 days (prostate), and 23 days (bladder), with differences observed across racial and ethnic groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among tested patients, actionable mutations were identified in 29% (NSCLC), 25% (prostate), and 14% (bladder) of patients, and targeted therapy was received by 54%, 15%, and 38% of these patients, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Genomic testing rates and BRCA yield: Dutch registry
Tissue availability for somatic genomic testing
“A total of 150 pts were enrolled. All had germline and initial ctDNA testing. Results from tissue testing were available in 72 pts.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Sequencing results from tissue were available in only half of pts, highlighting the challenges of obtaining tumor tissue for genomic testing.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Genomic test-directed olaparib: United States payer model
“Olaparib yielded an additional 0.063 and 0.068 of quality-adjusted life year (QALY) with the augmented cost of $7,382 and saved the cost of $ 1,980 compared to standard care in scenario A and B, respectively, which yielded an ICER of $116,903/QALY and a cost-saving option.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Included the NGS cost ($5,800).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Germline BRCA testing-guided olaparib: Australian payer model
“Compared to standard care, BRCA testing-guided olaparib treatment was associated with an incremental cost of AU$7,841 and a gain of 0.06 quality-adjusted life-years (QALYs). The incremental cost-effectiveness ratio (ICER) was AU$143,613 per QALY.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Germline BRCA testing with cascade testing of relatives: Australian payer model
“Compared with no testing, BRCA testing in mPCa was associated with an incremental cost of AU$3731 and a gain of 0.014 quality-adjusted life-years (QALYs), resulting in an incremental cost-effectiveness ratio of AU$265 942/QALY. Extending testing to FDRs of variant-positive patients resulted in an incremental cost-effectiveness ratio of AU$16 392/QALY.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cost per PSMA PET scan used in a United States model
| Imaging input | Cost (2021 USD) |
|---|---|
| Piflufolastat F 18 PET | “6274.17”View highlighted excerpt for this quote |
| Gallium 68 PSMA-11 PET | “6036.17”View highlighted excerpt for this quote |
| Fluciclovine F 18 PET | “6336.17”View highlighted excerpt for this quote |
| Computed tomography | “241.90”View highlighted excerpt for this quote |
PSMA PET cost-effectiveness in biochemical recurrence: United States model
“PSMA-PET had mean increments of $99 000 (95% UI, $55 000-153,000) in costs and 0.58 QALYs (95% UI, 0.35-0.82 QALYs) compared with CTBS, leading to an ICER of $172 000 per QALY, which exceeded the assumed $150 000/QALY willingness-to-pay threshold.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study found that PSMA-PET may be associated with improved disease detection but may not be cost-effective due to high treatment costs offsetting moderate improvements in QALYs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PSMA PET cost-effectiveness: systematic review
“A total of seven studies were examined, representing both private and public healthcare systems. Overall, these studies demonstrate high methodological and reporting quality. When compared to existing imaging technologies or standard care practices, PSMA-PET/CT or MRI is cost-effective within country-specific willingness-to-pay thresholds.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote